Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

bmiMD vs MadeMed

By GLP-1 ScorecardUpdated

bmiMDFactor scores not reassessed.
Site position #27

Lower score

MadeMed
Site position #35

Higher score

Score comparison

MadeMed has the higher recorded score — 80.4/100 to 79.2/100, but only just.

MadeMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MadeMed advertises all-dose pricing across 30-, 90- and 360-day purchases, with a consultation-fee conflict to resolve before prepaying. bmiMD is close behind and may still be the better fit — see the factor split below.

Before you choose

Before comparing the headline prices, the bmiMD review and the MadeMed review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, bmiMD vs NEUVÉ Health and Breeze Meds vs MadeMed compare each of them with another graded program, and the list of alternatives to bmiMD ranks the programs closest to bmiMD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valuebmiMD +14
88
74
Dose & formulationMadeMed +8
82
90
Clinical oversightMadeMed +14
70
84
Labs & monitoringbmiMD +10
72
62
FulfillmentMadeMed +6
84
90
Contract termsMadeMed +14
74
88
bmiMD · top barMadeMed · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricbmiMDMadeMed
WeighScore79.2/10080.4/100
GradeC+B−
Site position#27#35
Semaglutide$129/mo on the one-month plan ($99/mo equivalent with $1,188 prepaid for 12 months)$179 every 30 days; $483/90 days or $1,718/360 days ($143.17 equivalent per 30 days); consultation fees and usable supply require confirmation
Tirzepatide$179/mo on the one-month plan ($139/mo equivalent with $1,668 prepaid for 12 months)Injection or sublingual: $249 every 30 days; $672/90 days or $2,390/360 days ($199.17 equivalent per 30 days); final fees and supply unverified
CoverageAll 50 statesConfirm selected treatment/state: sublingual tirzepatide FAQ lists 40 states; current injection-state map unverified
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
bmiMD

Site position #27 · C+

Factor scores not reassessed.

Strengths

  • Advertises the same price across prescribed doses for each selected injection plan
  • Publishes compounded semaglutide and tirzepatide injection plans
  • Every rung of both ladders is published with the total charge beside each per-month figure
  • All 50 states

What to consider

  • The pricing block opens on the 3-Month tab, so the figure a reader meets first is a commitment rate rather than a month
  • The annual $99 and $139 monthly equivalents require $1,188 or $1,668 paid upfront for 12 months
  • A higher $229 and $349 monthly figure is printed beside every plan price under a standing LIMITED TIME label, with no published basis
  • Neither the compounding pharmacy nor the prescribing group is named on the product pages
MadeMed

Site position #35 · B−

Strengths

  • Public selectors show full charges for 30-, 90- and 360-day plans across the listed GLP-1 products
  • Advertises the same pricing across doses, ongoing clinical messaging and included injection supplies
  • Current terms name MDI Medical Group PC and four partner pharmacy brands
  • A 30-day purchase is advertised alongside the larger prepaid options

What to consider

  • Lowest advertised equivalents require $1,718/$2,390 360-day billing plans; terms reject prorated refunds
  • Product pages list $20/$30 consultation fees while How It Works says consultation is included and ineligible payments are refunded in full
  • The forty-state claim is specific to sublingual tirzepatide; an injection-state map was not established
  • Assigned clinician/pharmacy branch, patient lab costs, final first debit and usable prescription supply remain unresolved

Featured provider

bmiMD

Factor scores not reassessed.

bmiMD scores 79.2/100 (C+). bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard